MEERWALDT (University Hospital "Dijkzigt," 3015 GD Rotterdam, The Netherlands) write: Digoxin is a widely prescribed drug with narrow therapeutic margins, and intoxication is a common complication. We report a case ofsevere generalised chorea, agitation, and emotional disturbance due to digoxin excess.A 63 year old woman with a dissection of the ascending aorta had been treated conservatively for one month with digoxin 250 ig daily, labetalol 100 mg three times a day, dihydralazine 25 mg twice a day, isosorbide mononitrate 20 mg three times a day, bromazepam 1 5 mg three times a day, and triamterene one capsule daily. During the operation the defect of the intima was reconstructed with a haemoshield prosthesis (anaesthetic: fentanyl 36 ml and pancuronium 18 mg). The patient was haemodynamically stable immediately afterwards. Postoperatively she was treated with digoxin 250 [tg daily, triamterene one capsule daily, and, for three days, prednisolone acetate 25 mg daily. Three days after the operation she started to complain of extreme fatigue, showed no clouding of consciousness but was disoriented in time, appeared to be frightened, and had an impaired memory. Generalised symmetric choreatic movements increased in severity during the next few days to such an extent that she injured herself. The patient had neither been treated with neuroleptic drugs nor received other medication in the past which could have caused chorea. There was no history ofrheumatic fever. Computed tomography of the brain without contrast enhancement showed no abnormalities. Extensive laboratory values were repeatedly within normal ranges, except for urea and creatinine, which were temporarily raised, consistent with transient renal failure. The digoxin value, which had not been recorded previously, was 34 tg/l (therapeutic range 10-26 ,tg/l) one week after surgery. Digoxin was then discontinued and she was treated successfully with oral haloperidol 5 mg daily for one month. After the tapering off of haloperidol the abnormal involuntary movements did not return (follow up two years).There are only limited data on the relation between non-cardiac symptoms of digoxin toxicity and serum digitalis concentrations. ' Above 30 Fg/l (in our patient 34 [tg/l) there is a high incidence of intoxication, especially with renal failure.2 In contrast to a previously reported patient, who had hemichorea due to digoxin toxicity,3 our patient had generalised symmetric chorea. After the withdrawal of digoxin haloperidol was discontinued and the choreatic movements did not return. The fact that haloperidol controlled the choreatic movements might suggest that digoxin toxicity induces a functional alteration in the activity of dopamine at the synaptic level.4 The involvement of dopaminergic pathways might also explain the psychotic symptoms of digoxin intoxication, as in the more common organic brain syndromes.56 Digoxin toxicity should be included in the differential diagnosis of iatrogenic choreatic disorders.
An immunoradiometric assay (IRMA) involving a monoclonal antibody (MAb OC125) to an ovarian carcinoma-associated antigenic determinant (CA 125) has been tested as one component in a strategy for early detection of epithelial ovarian cancer. We characterized one confirmed "false-positive" sample by murine antibody blocking studies, Western blotting, immunoaffinity, size-exclusion chromatography, and reactivity with polyclonal rabbit antisera to CA 125 antigen. The positive response of this serum in the CA 125 IRMA was due to a human IgM. The discrepant IgM was isolated from the serum by successive immunoaffinity steps with nonspecific murine MAb, MAb OC125, and goat antibodies to human IgM Fc. Purified IgM inhibited the binding of MAb OC125 to CA 125. Furthermore, rabbit antisera to CA 125 antigen competitively inhibited the binding of MAb OC125 to both CA 125 and the discrepant IgM. The discrepant activity thus appears to reflect binding of this human IgM to a idiotope of MAb OC125. Radioiodination of MAb OC125 by a different technique eliminated the discrepant activity and decreased the incidence of CA 125 positivity in an at-risk population of apparently healthy women, increasing the specificity of the IRMA to 99.8% in this group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.